JP2013079270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013079270A5 JP2013079270A5 JP2012282406A JP2012282406A JP2013079270A5 JP 2013079270 A5 JP2013079270 A5 JP 2013079270A5 JP 2012282406 A JP2012282406 A JP 2012282406A JP 2012282406 A JP2012282406 A JP 2012282406A JP 2013079270 A5 JP2013079270 A5 JP 2013079270A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- formulation
- vegf
- histidine
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66512505P | 2005-03-25 | 2005-03-25 | |
| US60/665,125 | 2005-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Division JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013079270A JP2013079270A (ja) | 2013-05-02 |
| JP2013079270A5 true JP2013079270A5 (https=) | 2013-11-14 |
| JP5752671B2 JP5752671B2 (ja) | 2015-07-22 |
Family
ID=36678320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Expired - Lifetime JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
| JP2012282406A Expired - Lifetime JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Expired - Lifetime JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US20060217311A1 (https=) |
| EP (3) | EP2586459B1 (https=) |
| JP (2) | JP5376573B2 (https=) |
| KR (1) | KR101327270B1 (https=) |
| CN (2) | CN101141975B (https=) |
| AU (1) | AU2006229930C1 (https=) |
| CA (3) | CA3142945A1 (https=) |
| CY (2) | CY1116980T1 (https=) |
| DK (2) | DK1861116T3 (https=) |
| ES (2) | ES2633574T3 (https=) |
| HU (2) | HUE034109T2 (https=) |
| IL (2) | IL185606A (https=) |
| LT (1) | LT2586459T (https=) |
| NZ (1) | NZ560713A (https=) |
| PL (2) | PL1861116T3 (https=) |
| PT (2) | PT1861116E (https=) |
| SI (2) | SI2586459T1 (https=) |
| WO (1) | WO2006104852A2 (https=) |
| ZA (1) | ZA200708845B (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572893B2 (en) * | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| AU2012202859C1 (en) * | 2006-06-16 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| EP2612867A1 (en) | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| BRPI0921469B1 (pt) * | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| CN102552875B (zh) * | 2010-12-09 | 2015-05-20 | 上海国健生物技术研究院 | 一种双功能vegf受体融合蛋白制剂 |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CA2833144C (en) * | 2011-04-14 | 2020-09-29 | The Regents Of The University Of California | Multilayer thin film drug delivery device and methods of making and using the same |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| EP3539374A1 (en) * | 2012-03-16 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
| AU2013298521A1 (en) * | 2012-08-02 | 2015-02-26 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN103110105A (zh) * | 2012-11-14 | 2013-05-22 | 江苏江山制药有限公司 | 食品添加剂无糖维生素c钠盐颗粒的生产方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EA035674B1 (ru) | 2014-07-18 | 2020-07-24 | Санофи | Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| MX2017009759A (es) | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US10576128B2 (en) * | 2016-01-26 | 2020-03-03 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| KR102605317B1 (ko) | 2016-10-07 | 2023-11-24 | 리제너론 파아마슈티컬스, 인크. | 실온 안정성 동결건조된 단백질 |
| JP7116059B2 (ja) * | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| USD849856S1 (en) | 2017-06-28 | 2019-05-28 | Jumpsport, Inc. | Standing platform |
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| WO2019124946A1 (ko) | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| EP3761953A1 (en) | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| DK4364724T3 (da) * | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| KR102337471B1 (ko) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CA3190325A1 (en) * | 2020-07-31 | 2022-02-03 | Celltrion Inc. | Stable pharmaceutical preparation |
| CN120204358A (zh) * | 2023-12-27 | 2025-06-27 | 成都康弘生物科技有限公司 | 一种含有抗vegf的融合蛋白的药物组合物 |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| WO2025227916A1 (zh) | 2024-04-29 | 2025-11-06 | 齐鲁制药有限公司 | 包含阿柏西普和其变体的组合物以及相关方法和应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) * | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JPH10273450A (ja) | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| ATE420177T1 (de) | 1999-04-16 | 2009-01-15 | Genentech Inc | Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| WO2004087206A2 (en) * | 2003-03-28 | 2004-10-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking vegf-mediated activity |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2004103159A2 (en) * | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| ITMI20031261A1 (it) | 2003-06-20 | 2004-12-21 | Messersi Packaging Srl | Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia. |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| WO2005016369A1 (en) | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| EP1732947B1 (en) | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
| WO2005102303A2 (en) | 2004-04-21 | 2005-11-03 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| CA2567686A1 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| AU2005267741A1 (en) | 2004-07-30 | 2006-02-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| US7303748B2 (en) * | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| MX368442B (es) | 2014-01-25 | 2019-10-02 | Chengdu Kanghong Biotechnologies Co Ltd | Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma. |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2006
- 2006-03-22 ES ES13152402.7T patent/ES2633574T3/es not_active Expired - Lifetime
- 2006-03-22 CN CN2006800085696A patent/CN101141975B/zh not_active Expired - Lifetime
- 2006-03-22 SI SI200632195T patent/SI2586459T1/sl unknown
- 2006-03-22 CN CN201210090068.4A patent/CN102614134B/zh not_active Expired - Lifetime
- 2006-03-22 AU AU2006229930A patent/AU2006229930C1/en active Active
- 2006-03-22 WO PCT/US2006/010600 patent/WO2006104852A2/en not_active Ceased
- 2006-03-22 ZA ZA200708845A patent/ZA200708845B/xx unknown
- 2006-03-22 KR KR1020077024202A patent/KR101327270B1/ko not_active Expired - Lifetime
- 2006-03-22 PL PL06748594T patent/PL1861116T3/pl unknown
- 2006-03-22 CA CA3142945A patent/CA3142945A1/en active Pending
- 2006-03-22 ES ES06748594.6T patent/ES2548238T3/es not_active Expired - Lifetime
- 2006-03-22 DK DK06748594.6T patent/DK1861116T3/en active
- 2006-03-22 EP EP13152402.7A patent/EP2586459B1/en not_active Expired - Lifetime
- 2006-03-22 LT LTEP13152402.7T patent/LT2586459T/lt unknown
- 2006-03-22 CA CA2598711A patent/CA2598711C/en not_active Expired - Lifetime
- 2006-03-22 PL PL13152402T patent/PL2586459T3/pl unknown
- 2006-03-22 HU HUE13152402A patent/HUE034109T2/en unknown
- 2006-03-22 SI SI200631996T patent/SI1861116T1/sl unknown
- 2006-03-22 US US11/387,256 patent/US20060217311A1/en not_active Abandoned
- 2006-03-22 HU HUE06748594A patent/HUE027096T2/en unknown
- 2006-03-22 DK DK13152402.7T patent/DK2586459T3/en active
- 2006-03-22 NZ NZ560713A patent/NZ560713A/en not_active IP Right Cessation
- 2006-03-22 EP EP17159239.7A patent/EP3195874A1/en not_active Ceased
- 2006-03-22 EP EP06748594.6A patent/EP1861116B1/en not_active Expired - Lifetime
- 2006-03-22 PT PT67485946T patent/PT1861116E/pt unknown
- 2006-03-22 CA CA2995971A patent/CA2995971A1/en active Pending
- 2006-03-22 JP JP2008503191A patent/JP5376573B2/ja not_active Expired - Lifetime
- 2006-03-22 PT PT131524027T patent/PT2586459T/pt unknown
-
2007
- 2007-08-30 IL IL185606A patent/IL185606A/en active IP Right Grant
-
2010
- 2010-07-13 US US12/835,065 patent/US8110546B2/en not_active Expired - Lifetime
-
2012
- 2012-01-04 US US13/343,214 patent/US8404638B2/en not_active Expired - Lifetime
- 2012-03-23 US US13/428,510 patent/US8710004B2/en not_active Expired - Lifetime
- 2012-12-26 JP JP2012282406A patent/JP5752671B2/ja not_active Expired - Lifetime
-
2013
- 2013-06-04 US US13/909,745 patent/US8921316B2/en not_active Expired - Lifetime
- 2013-06-27 IL IL227215A patent/IL227215A/en active IP Right Grant
-
2014
- 2014-11-21 US US14/550,385 patent/US9416167B2/en not_active Expired - Lifetime
-
2015
- 2015-11-26 CY CY20151101068T patent/CY1116980T1/el unknown
-
2016
- 2016-03-08 US US15/064,343 patent/US9511140B2/en not_active Expired - Lifetime
- 2016-05-10 US US15/150,840 patent/US9636400B2/en not_active Expired - Fee Related
- 2016-11-03 US US15/342,989 patent/US20170073407A1/en not_active Abandoned
-
2017
- 2017-08-02 CY CY20171100827T patent/CY1119243T1/el unknown
- 2017-08-31 US US15/692,893 patent/US10406226B2/en not_active Expired - Lifetime
-
2019
- 2019-08-08 US US16/535,610 patent/US10857231B2/en not_active Expired - Lifetime
-
2020
- 2020-11-17 US US16/950,584 patent/US11806398B2/en active Active
-
2021
- 2021-05-04 US US17/307,240 patent/US20210252147A1/en not_active Abandoned
- 2021-05-05 US US17/308,801 patent/US20210252105A1/en not_active Abandoned
- 2021-05-06 US US17/313,627 patent/US20210393778A1/en not_active Abandoned
- 2021-05-07 US US17/314,992 patent/US20210393530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013079270A5 (https=) | ||
| JP2009540001A5 (https=) | ||
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| MX374287B (es) | Formulacion que contiene virus y uso de la misma. | |
| JP2009292810A5 (https=) | ||
| CN102580062B (zh) | 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂 | |
| JP2012515221A5 (https=) | ||
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| FI3725330T3 (fi) | Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2014530010A5 (https=) | ||
| IL242372B2 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
| RU2016105462A (ru) | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства | |
| RU2017125931A (ru) | Фармацевтическая композиция, содержащая плазминоген, и ее применение | |
| JP2008510716A5 (https=) | ||
| HRP20190954T1 (hr) | Stabilne formulacije imunoglobulinskih jednostrukih varijabilnih domena i njihove uporabe | |
| RU2016131667A (ru) | Состав препарата нейрегулина | |
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2012136518A5 (https=) | ||
| JP2013537212A5 (https=) | ||
| JP2016533345A5 (https=) | ||
| JP2017510585A5 (https=) | ||
| CN101631563A (zh) | 含有流感疫苗的冻干制剂及其制备方法 |